Teva Pharmaceuticals Beats Q3 Expectations as Branded Drug Strategy Pays Off
Teva Pharmaceuticals (TEVA) Q3 2025 earnings beat expectations with 33% growth in branded drugs led by Austedo. Stock surges 12% as innovative portfolio drives transformation.